Navigation Links
University of Cincinnati leads first trial on steroid and CNI withdrawal post-transplant
Date:11/28/2012

CINCINNATIThe University of Cincinnati will lead a $5.2 million national trial studying removal of both corticosteroids and common immunosuppression treatments from the post-transplant drug regimen for kidney transplant patients.

The Belatacept Early Steroid withdrawal Trial (BEST) seeks to determine if a belatacept-based regimen for post-transplant patients can prevent organ rejection without the harmful side effects posed by corticosteroids and calcineurin inhibitor (CNI) immunosuppressants. Belatacept is a modified version of the drug abatacept, which is used to treat rheumatoid arthritis.

Led by principal investigator and director of UC's division of transplantation E. Steve Woodle, MD, the $5.2 million trial will be carried out at four other transplant centers across the country: University of Wisconsin, University of Minnesota, California Pacific Medical Center and the Christ Hospital in Cincinnati.

The BEST study is the first large, multicenter trial to remove both corticosteroids and CNIs from a patient's drug regimen after kidney transplantation. Both drugs place patients at an increased risk of cardiovascular disease, high blood pressure, high cholesterol and diabetes. Additionally, CNIs have shown toxicity to transplanted kidneys.

"Cardiovascular events like stroke and heart attacks are the top cause of death for both the general population and transplant patients," says Woodle, who also serves as William A. Altemeier Chair in the UC Department of Surgery. "We've previously demonstrated that early steroid withdrawal results in reduced rates of rejection and increased graft survival in transplant patients."

Rita Alloway, PharmD, research professor of medicine and director of transplant clinical research within the UC Department of Internal Medicine, will direct the coordinating center for the trial. She says belatacept was approved by the Food and Drug Administration in 2011 for prevention of rejection in kidney transplant patientsthe first FDA-approved drug to replace CNIs like tacrolimus and cyclosporine.

"This trial is a major step forward in immunosuppression because it provides a means to avoid many of the toxicities of the CNI drugs, particularly kidney toxicity, high blood pressure, and hyperlipidemia," says Alloway.

Adele Shields, PhD, associate research professor of surgery with clinical practice at the Christ Hospital, has specialized in quantitating the impact of long-term immunosuppression on cardiac risk factors and cardiac events.

"An important feature of the belatacept-based treatment regimen is that it provides an opportunity to greatly minimize cardiovascular risk in the long term," she says. "By avoiding both CNIs and corticosteroids, this trial provides an opportunity to substantially impact long-term patient survival following kidney transplantation."


'/>"/>

Contact: Kathryn Cosse
kathryn.cosse@uc.edu
513-558-0207
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Thomas Jefferson University honoring Axel Ullrich with Lennox K. Black International Prize
2. University Hospitals & Philips Healthcare to showcase imaging technology at Cleveland Medical Mart
3. University of Tennessee study: Unexpected microbes fighting harmful greenhouse gas
4. Scientists at Mainz University identify inhibitor of myelin formation in the central nervous system
5. University of Pennsylvania Medicine receives National Institutes of Health grant to help local communities move forward after asbestos exposure
6. Allied Minds and The George Washington University partner to form LuxCath LLC
7. New era in metabolomics begins at University of Michigan
8. Umeå University hosts new World Health Organization Collaborating Centre
9. George Mason University researchers target breast cancer in 3 trials
10. Research prizes from the Carlsberg Foundation to researchers from University of Copenhagen
11. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2019)... MONROE, Conn. (PRWEB) , ... September 09, 2019 ... ... celebrates 30 years of serving Monroe, CT with advanced gum disease treatment ... at the forefront of innovative technology, providing the most cutting-edge treatment available for ...
(Date:9/8/2019)... ... ... Stetson University ranks No. 5 on U.S. News & World Report’s ... Stetson appears on five additional lists in the same category: Best Undergraduate Teaching, No. ... No. 34; and a new list this year, Top Performers on Social Mobility, No. ...
(Date:9/8/2019)... Calif. (PRWEB) , ... September 06, 2019 , ... The ... tremendously positive! The high success rate for this non-invasive and pain free fat loss ... lose the unwanted fat in problem areas. , Contoura uses state of the art ...
(Date:9/8/2019)... ... 07, 2019 , ... Messaging Architects, an eMazzanti Technologies Company ... successful GroupWise to Office 365 email migration on the Messaging Architects website. The ... organization. , The informative article discusses the tight timeline faced by the Messaging ...
(Date:9/4/2019)... ... 2019 , ... Dental portal DrBicuspid.com, part of Science and Medicine Group, has ... prepare for the new 2020 Integrated National Board Dental Exam (INBDE). Dental Exam is ... must pass a board certification exam in order to become licensed to practice dentistry ...
Breaking Medicine News(10 mins):
(Date:9/11/2019)... NASHVILLE, Tenn. (PRWEB) , ... September 11, 2019 ... ... addition of Jeff Maris to lead its Cerner Strategic Implementation and Partnerships ... delivery as a Technology Sales Executive who expanded Cerner’s CareAware business and as ...
(Date:9/9/2019)... ... September 09, 2019 , ... New ... Dental Implants host the latest course in their Synergy Study Club, called “Truth ... features guest speaker Dr. Peter Barndt. Synergy Study Club brings together leading specialists ...
(Date:9/9/2019)... ... 09, 2019 , ... Dr. Jin Kim of Garden Grove, ... in Tilburg, Netherlands. A dual-board certified periodontist, Dr. Kim spoke about the application ... periodontics. At his practices in Diamond Bar and Garden Grove, CA, Dr. Kim ...
Breaking Medicine Technology: